Stock ALXO ALX ONCOLOGY HOLDINGS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Real-time Estimate Cboe BZX
Other stock markets
 01:06:59 2024-06-06 pm EDT 		5-day change 1st Jan Change
8.75 USD -0.57% Intraday chart for ALX Oncology Holdings Inc. -18.12% -41.44%
Jun. 02 ALX Oncology Holdings Inc. Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 Aspen-07 Clinical Trial in Patients with Advanced Bladder Cancer CI
May. 09 ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
AQ
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
GL
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
GL
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
AQ
ALX Oncology : Corporate Presentation
PU
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
GL
ALX Oncology Appoints Allison Dillon as Chief Business Officer
GL
ALX Oncology Appoints Allison Dillon as Chief Business Officer
AQ
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
GL
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
AQ
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
GL
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
GL
ALX Oncology : Corporate Presentation
PU
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GL
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
GL
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
AQ
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GL
ALX Oncology Announces November Investor Conference Participation
GL
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALXO Stock
  4. News ALX Oncology Holdings Inc.
  5. Press Releases